Skip to content
Back to treatments
Transplant & Hematology~84% less than U.S.

Thalassemia Treatment

地中海贫血治疗

Duration
HSCT: 4-6 weeks inpatient; Medical management: lifelong
Recovery
HSCT: 3-6 months for immune recovery; transfusion independence achieved post-engraftment
Average savings
84%
价格对比Price comparison

China versus the U.S.

China
$40,000
Range: $20,000–$60,000
United States
$250,000
Range: $100,000–$400,000
You save
84%
~$210,000 per procedure
China clinical rate
$20,000 – $60,000
$40,000
United States
$100,000 – $400,000
$250,000
You save
~84%
$210,000 per procedure

Prices are approximate ranges. Actual cost depends on hospital, surgeon, materials, and case complexity.

关于About this treatment

What the procedure involves.

Comprehensive thalassemia management including optimized transfusion therapy, iron chelation, and curative allogeneic hematopoietic stem cell transplantation. Southern China (Guangxi, Guangdong, Hainan) has the highest thalassemia prevalence globally, resulting in world-leading clinical expertise and transplant volumes. Gene therapy clinical trials using CRISPR-based approaches are also underway at select centers, offering potential future cures without donor dependency.

流程Procedure steps

Step by step.

  1. 01

    Disease Characterization & Iron Assessment

    Hemoglobin electrophoresis, genetic mutation analysis, cardiac/liver MRI T2* for iron quantification, and ferritin trending

    Duration · 3-5 days
  2. 02

    Transplant Evaluation (curative intent)

    Pesaro risk classification, donor search and HLA matching, organ function assessment, and iron reduction if needed

    Duration · 1-2 weeks
  3. 03

    Conditioning & Transplant

    Myeloablative conditioning followed by matched sibling, unrelated, or haploidentical stem cell infusion

    Duration · 4-6 weeks
  4. 04

    Post-Transplant Monitoring

    Engraftment confirmation, chimerism assessment, GVHD prophylaxis tapering, and iron overload management post-cure

    Duration · 6-12 months
Benefits
  • World-leading thalassemia transplant experience in southern China
  • Cure rates exceeding 90% for low-risk patients with matched donors
  • CRISPR gene therapy trials available at select centers
  • Comprehensive iron overload management expertise
Considerations
  • HSCT carries graft rejection and GVHD risks
  • Pre-existing iron overload increases transplant complications
  • Gene therapy is still experimental with limited long-term data
  • Mixed chimerism may result in partial transfusion dependence
下一步Next step

Ask the AI for hospitals that handle thalassemia treatment.

Prices shown are approximate ranges for reference only. Actual costs vary by hospital, complexity, and individual patient needs. Always consult with healthcare professionals for medical decisions.